Takeda Pharmaceutical Co Ltd ADR (TAK) financial statements

Healthcare · Drug Manufacturers - Specialty & Generic · Market cap $59.3B

Takeda Pharmaceutical Co Ltd ADR reported revenue of 4.58T JPY in fiscal 2025, up 12.9% a year over 8 years.

Net income was 107.9B JPY and the operating margin 7.5%, against 9.0% in 2017.

Free cash flow was 709.3B JPY, and the company returned 302.5B JPY in dividends and 51.9B JPY in net buybacks.

The diluted share count rose 104% over the period (dilution).

Revenue and free cash flow

Fiscal years, $ billions (JPY).

Embed this chart

Free to use in articles and newsletters with the source line. Paste this HTML:

<iframe src="https://investingly.io/embed/TAK/financials" width="100%" height="330" style="border:0;max-width:680px" title="Takeda Pharmaceutical Co Ltd ADR revenue and free cash flow" loading="lazy"></iframe>
<p style="font-size:13px">Source: <a href="https://investingly.io/stocks/TAK/financials">Takeda Pharmaceutical Co Ltd ADR financials</a> on Investingly</p>

Income statement

Fiscal years, in JPY, from Takeda Pharmaceutical Co Ltd ADR's 10-K filings with the SEC.

Fiscal year	2017	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	1.73T JPY	1.77T JPY	2.10T JPY	3.29T JPY	3.20T JPY	3.57T JPY	4.03T JPY	4.26T JPY	4.58T JPY
Cost of revenue	558.8B JPY	495.9B JPY	651.7B JPY	1.09T JPY	994.3B JPY	1.11T JPY	1.24T JPY	1.43T JPY	1.58T JPY
Gross profit	1.17T JPY	1.27T JPY	1.45T JPY	2.20T JPY	2.20T JPY	2.46T JPY	2.78T JPY	2.84T JPY	3.00T JPY
Research and development	312.3B JPY	325.4B JPY	368.3B JPY	492.4B JPY	455.8B JPY	526.1B JPY	633.3B JPY	729.9B JPY	730.2B JPY
Selling, general and admin	619.1B JPY	628.1B JPY	717.6B JPY	964.7B JPY	875.7B JPY	886.4B JPY	997.3B JPY	1.05T JPY	1.10T JPY
Operating income	155.9B JPY	241.8B JPY	237.7B JPY	100.4B JPY	509.3B JPY	460.8B JPY	490.5B JPY	214.1B JPY	342.6B JPY
Interest expense	7.6B JPY	10.0B JPY	48.2B JPY	149.0B JPY	130.8B JPY	122.4B JPY	117.0B JPY	119.5B JPY	137.3B JPY
Pre-tax income	143.3B JPY	217.2B JPY	127.6B JPY	-60.8B JPY	366.2B JPY	302.6B JPY	375.1B JPY	52.8B JPY	175.1B JPY
Income tax	27.8B JPY	30.5B JPY	-7.5B JPY	-105.0B JPY	-9.9B JPY	72.4B JPY	58.1B JPY	-91.4B JPY	66.9B JPY
Net income	114.9B JPY	186.9B JPY	135.2B JPY	44.2B JPY	376.0B JPY	230.1B JPY	317.0B JPY	144.1B JPY	107.9B JPY
EPS (diluted)	146.26 JPY	237.56 JPY	139.82 JPY	28.25 JPY	238.96 JPY	145.87 JPY	201.94 JPY	91.16 JPY	67.23 JPY
Diluted shares	786M	787M	967M	1.57B	1.57B	1.58B	1.57B	1.58B	1.61B
Gross margin	67.7%	72.0%	68.9%	66.9%	68.9%	69.0%	69.1%	66.5%	65.5%
Operating margin	9.0%	13.7%	11.3%	3.1%	15.9%	12.9%	12.2%	5.0%	7.5%
Net margin	6.6%	10.6%	6.4%	1.3%	11.8%	6.4%	7.9%	3.4%	2.4%

Balance sheet

Fiscal years, in JPY, from Takeda Pharmaceutical Co Ltd ADR's 10-K filings with the SEC.

Fiscal year	2017	2018	2019	2020	2021	2022	2023	2024	2025
Cash and short-term investments	319.5B JPY	294.5B JPY	702.1B JPY	637.6B JPY	966.2B JPY	849.7B JPY	533.5B JPY	457.8B JPY	385.1B JPY
Receivables	—	420.2B JPY	741.9B JPY	757.0B JPY	783.1B JPY	696.6B JPY	649.4B JPY	668.4B JPY	709.5B JPY
Inventory	—	212.9B JPY	919.7B JPY	759.6B JPY	753.9B JPY	853.2B JPY	986.5B JPY	1.21T JPY	1.22T JPY
Total current assets	—	1.08T JPY	2.99T JPY	2.47T JPY	2.71T JPY	2.59T JPY	2.40T JPY	2.56T JPY	2.52T JPY
Property, plant and equipment	—	536.8B JPY	1.33T JPY	1.39T JPY	1.45T JPY	1.58T JPY	1.69T JPY	1.99T JPY	1.97T JPY
Goodwill	—	1.03T JPY	4.24T JPY	4.01T JPY	4.03T JPY	4.41T JPY	4.79T JPY	5.41T JPY	5.32T JPY
Total assets	—	4.11T JPY	13.79T JPY	12.82T JPY	12.91T JPY	13.18T JPY	13.96T JPY	15.11T JPY	14.25T JPY
Total current liabilities	—	737.5B JPY	2.55T JPY	2.18T JPY	1.77T JPY	2.15T JPY	2.48T JPY	2.31T JPY	2.51T JPY
Long-term debt	—	985.6B JPY	4.77T JPY	4.51T JPY	4.61T JPY	4.14T JPY	4.04T JPY	4.48T JPY	3.97T JPY
Total liabilities	—	2.09T JPY	8.61T JPY	8.09T JPY	7.74T JPY	7.49T JPY	7.60T JPY	7.83T JPY	7.31T JPY
Shareholders' equity	1.95T JPY	2.00T JPY	5.18T JPY	4.72T JPY	5.17T JPY	5.68T JPY	6.35T JPY	7.27T JPY	6.94T JPY
Net debt	-319.5B JPY	691.1B JPY	5.05T JPY	4.46T JPY	3.67T JPY	3.50T JPY	3.85T JPY	4.39T JPY	4.13T JPY

Cash flow

Fiscal years, in JPY, from Takeda Pharmaceutical Co Ltd ADR's 10-K filings with the SEC.

Fiscal year	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating cash flow	261.4B JPY	377.9B JPY	328.5B JPY	669.8B JPY	1.01T JPY	1.12T JPY	977.2B JPY	716.3B JPY	1.06T JPY
Capital spending	112.0B JPY	128.3B JPY	134.1B JPY	217.7B JPY	236.5B JPY	186.0B JPY	633.7B JPY	480.7B JPY	347.8B JPY
Free cash flow	149.3B JPY	249.6B JPY	194.4B JPY	452.0B JPY	774.5B JPY	937.1B JPY	343.5B JPY	235.6B JPY	709.3B JPY
Dividends paid	141.7B JPY	141.9B JPY	143.0B JPY	282.6B JPY	283.4B JPY	283.7B JPY	279.4B JPY	287.2B JPY	302.5B JPY
Share buybacks (net)	-23.1B JPY	-18.8B JPY	-1.2B JPY	-3.7B JPY	-2.1B JPY	-77.5B JPY	-26.9B JPY	-2.3B JPY	-51.9B JPY
Net borrowing	68.5B JPY	253.5B JPY	2.80T JPY	-204.9B JPY	-472.2B JPY	-560.8B JPY	-281.7B JPY	-220.9B JPY	-296.6B JPY
Free cash flow margin	8.6%	14.1%	9.3%	13.7%	24.2%	26.3%	8.5%	5.5%	15.5%
Dividends per share	180.29 JPY	180.36 JPY	147.85 JPY	180.42 JPY	180.08 JPY	179.86 JPY	177.99 JPY	181.73 JPY	188.43 JPY

Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for TAK.

Open TAK in Investingly

Questions

What was Takeda Pharmaceutical Co Ltd ADR's revenue in 2025?

4.58T JPY in fiscal 2025, from its 10-K filing.

How much free cash flow does Takeda Pharmaceutical Co Ltd ADR generate?

709.3B JPY in fiscal 2025 (operating cash flow minus capital spending).

From Takeda Pharmaceutical Co Ltd ADR's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.